Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E C Kohn

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|July 23, 2013
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactionsD H Moon, J-M Lee, A M Noonan, et al.
Blood|March 1, 1994
Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapyC J Link, A Bicher, E C Kohn, et al.
Biochemical and Biophysical Research Communications|June 30, 1988
Insulin-like growth factors stimulate chemotaxis in human melanoma cellsM L Stracke, E C Kohn, S A Aznavoorian, et al.
The Journal of Biological Chemistry|May 5, 1992
The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cellsC P Minniti, E C Kohn, J H Grubb, et al.
Cancer|November 7, 1998
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancerJ D Shapiro, M L Rothenberg, G A Sarosy, et al.
Journal of the National Cancer Institute|January 5, 1994
Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancerE C Kohn, G Sarosy, A Bicher, et al.
International Journal of Cancer|October 9, 1996
Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell linesW J Wasilenko, A J Palad, K D Somers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulationsE C Kohn, W D Figg, G A Sarosy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazoleY Wu, A J Palad, W J Wasilenko, et al.
Angiogenesis|October 1, 2003
Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI)K J Luzzi, H J Varghese, I C MacDonald, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|July 23, 2013
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactionsD H Moon, J-M Lee, A M Noonan, et al.
Blood|March 1, 1994
Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapyC J Link, A Bicher, E C Kohn, et al.
Biochemical and Biophysical Research Communications|June 30, 1988
Insulin-like growth factors stimulate chemotaxis in human melanoma cellsM L Stracke, E C Kohn, S A Aznavoorian, et al.
The Journal of Biological Chemistry|May 5, 1992
The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cellsC P Minniti, E C Kohn, J H Grubb, et al.
Cancer|November 7, 1998
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancerJ D Shapiro, M L Rothenberg, G A Sarosy, et al.
Journal of the National Cancer Institute|January 5, 1994
Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancerE C Kohn, G Sarosy, A Bicher, et al.
International Journal of Cancer|October 9, 1996
Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell linesW J Wasilenko, A J Palad, K D Somers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulationsE C Kohn, W D Figg, G A Sarosy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazoleY Wu, A J Palad, W J Wasilenko, et al.
Angiogenesis|October 1, 2003
Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI)K J Luzzi, H J Varghese, I C MacDonald, et al.
Pageof 8